Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MIRM Stock 12 Month Forecast
Average Price Target
$80.80
▲(8.89% Upside)
| Highest Price Target$89.00 | Average Price Target$80.80 | Lowest Price Target$66.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$67→$74
Hold
-0.27%
Downside
Reiterated
08/23/25
Citi
$89
Buy
19.95%
Upside
Reiterated
08/18/25
Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)We hosted Mirum co-founder and CEO a virtual fireside chat (replay HERE). We discussed the company’s rare disease franchise specializing in developing ileal bile acid transporter (IBATs) to target cholestatic disorders, which are caused by bile acid buildup due to reduced/blocked flow from the liver. IBATs can significantly decrease the debilitating itching (aka pruritus) symptoms experienced by patients. Mirum’s primary asset in Livmarli is approved for two cholestatic genetic diseases and has been outperforming sales expectations over the past few quarters, bringing in $88.2M most recently in 2Q25. Mgt believes a potential label expansion for Livmarli to patients with other ultra-rare choleastic diseases could propel the drug to blockbuster status.
Evercore ISI
$89
Buy
19.95%
Upside
Reiterated
08/11/25
Earnings Overload SMID Biotech Week in Review
Stifel Nicolaus
$89
Buy
19.95%
Upside
Initiated
08/11/25
H.C. Wainwright
$73→$80
Buy
7.82%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$75→$85
Buy
14.56%
Upside
Reiterated
08/07/25
Citizens JMP
$79→$81
Buy
9.16%
Upside
Reiterated
08/07/25
Raymond James
$77→$82
Buy
10.51%
Upside
Reiterated
08/07/25
Morgan Stanley
$70→$75
Buy
1.08%
Upside
Reiterated
08/07/25
Leerink Partners
$56→$66
Buy
-11.05%
Downside
Reiterated
08/07/25
Robert W. Baird
$55→$72
Buy
-2.96%
Downside
Reiterated
08/07/25
J.P. Morgan
$53
Buy
-28.57%
Downside
Reiterated
04/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$67→$74
Hold
-0.27%
Downside
Reiterated
08/23/25
Citi
$89
Buy
19.95%
Upside
Reiterated
08/18/25
Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)We hosted Mirum co-founder and CEO a virtual fireside chat (replay HERE). We discussed the company’s rare disease franchise specializing in developing ileal bile acid transporter (IBATs) to target cholestatic disorders, which are caused by bile acid buildup due to reduced/blocked flow from the liver. IBATs can significantly decrease the debilitating itching (aka pruritus) symptoms experienced by patients. Mirum’s primary asset in Livmarli is approved for two cholestatic genetic diseases and has been outperforming sales expectations over the past few quarters, bringing in $88.2M most recently in 2Q25. Mgt believes a potential label expansion for Livmarli to patients with other ultra-rare choleastic diseases could propel the drug to blockbuster status.
Evercore ISI
$89
Buy
19.95%
Upside
Reiterated
08/11/25
Earnings Overload SMID Biotech Week in Review
Stifel Nicolaus
$89
Buy
19.95%
Upside
Initiated
08/11/25
H.C. Wainwright
$73→$80
Buy
7.82%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$75→$85
Buy
14.56%
Upside
Reiterated
08/07/25
Citizens JMP
$79→$81
Buy
9.16%
Upside
Reiterated
08/07/25
Raymond James
$77→$82
Buy
10.51%
Upside
Reiterated
08/07/25
Morgan Stanley
$70→$75
Buy
1.08%
Upside
Reiterated
08/07/25
Leerink Partners
$56→$66
Buy
-11.05%
Downside
Reiterated
08/07/25
Robert W. Baird
$55→$72
Buy
-2.96%
Downside
Reiterated
08/07/25
J.P. Morgan
$53
Buy
-28.57%
Downside
Reiterated
04/04/25
Best Analysts Covering Mirum Pharmaceuticals
1 Month
xxx
Success Rate
17/34 ratings generated profit
Average Return
+3.14%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.14% per trade.
3 Months
xxx
Success Rate
22/34 ratings generated profit
Average Return
+7.56%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +7.56% per trade.
1 Year
Success Rate
17/17 ratings generated profit
Average Return
+50.28%
reiterated a buy rating 22 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +50.28% per trade.
2 Years
xxx
Success Rate
17/17 ratings generated profit
Average Return
+107.69%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +107.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MIRM Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
8
7
6
0
Buy
9
3
2
2
12
Hold
7
9
8
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
20
17
16
20
Each month's total comprises the sum of three months' worth of ratings.
MIRM Financial Forecast
MIRM Stock Forecast FAQ
What is MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 80.80.
What is MIRM’s upside potential, based on the analysts’ average price target?
Mirum Pharmaceuticals Inc has 8.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MIRM a Buy, Sell or Hold?
Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mirum Pharmaceuticals Inc’s price target?
The average price target for Mirum Pharmaceuticals Inc is 80.80. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $89.00 ,the lowest forecast is $66.00. The average price target represents 8.89% Increase from the current price of $74.2.
The highest analyst price target is $89.00 ,the lowest forecast is $66.00. The average price target represents 8.89% Increase from the current price of $74.2.
What do analysts say about Mirum Pharmaceuticals Inc?
Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of MIRM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.